NIH launches large clinical trial for immune modulators as COVID-19 treatments
The National Institutes of Health today announced the start of an adaptive phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19.
NIH said the ACTIV-1 Immune Modulators trial will seek to determine if modulating immune responses that trigger so-called cytokine storms can reduce the need for ventilators and shorten hospital stays and whether the trialed therapeutics are able to restore balance to an overactive immune system.
Related News Articles
Perspective
We’ve been discussing for months how hospitals and health systems are contending with the worst financial crisis in their history as they continue to serve on…
Headline
The Centers for Medicare & Medicaid Services yesterday issued a final rule updating the home health prospective payment system for calendar year 2021.…
Headline
The Federal Reserve Board today reduced the minimum loan size for three Main Street Lending Program facilities from $250,000 to $100,000 and adjusted…
Headline
“The COVID-19 pandemic has proved that crisis tends to be a driver of innovation,” writes Jonathan Bandel, vice president of strategy and innovation for New…
Headline
The Food and Drug Administration Wednesday updated its guidance on enforcement policy for non-invasive remote monitoring devices that support patient…
Headline
Over 10,000 eligible nursing homes, or 76% of the field, will receive a portion of $333 million in COVID-19 Provider Relief Funds for meeting infection control…